Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A protein–protein interface is the specific surface region where two protein molecules come into direct contact and interact via non-covalent forces such as hydrophobic interactions, hydrogen bonds, and electrostatic forces. These interfaces are essential to virtually all cellular processes, enabling the formation of protein complexes involved in signaling, structural assembly, enzymatic regulation, and more. Unlike defined molecular targets (receptors, enzymes), protein–protein interfaces are not single gene products but three-dimensional arrangements of amino acids from each interacting protein. Aberrant PPIs are linked to diseases including cancer, neurodegeneration, and infections, making them a major focus for innovative drug development despite significant druggability challenges[1][3][5].
Disruption/inhibition of protein–protein interaction (PPI inhibitors); Stabilization of protein–protein interaction (PPI stabilizers); Allosteric modulation affecting interface conformation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein–protein interface (PPI interface).